BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 19244114)

  • 1. Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells.
    Gaspar N; Sharp SY; Pacey S; Jones C; Walton M; Vassal G; Eccles S; Pearson A; Workman P
    Cancer Res; 2009 Mar; 69(5):1966-75. PubMed ID: 19244114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition.
    Guo W; Reigan P; Siegel D; Zirrolli J; Gustafson D; Ross D
    Cancer Res; 2005 Nov; 65(21):10006-15. PubMed ID: 16267026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of NQO1 status as a selective biomarker for oesophageal squamous cell carcinomas with greater sensitivity to 17-AAG.
    Hadley KE; Hendricks DT
    BMC Cancer; 2014 May; 14():334. PubMed ID: 24886060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylase activity mediates acquired resistance towards structurally diverse HSP90 inhibitors.
    Chai RC; Vieusseux JL; Lang BJ; Nguyen CH; Kouspou MM; Britt KL; Price JT
    Mol Oncol; 2017 May; 11(5):567-583. PubMed ID: 28306192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acquired resistance to HSP90 inhibitor 17-AAG and increased metastatic potential are associated with MUC1 expression in colon carcinoma cells.
    Liu X; Ban LL; Luo G; Li ZY; Li YF; Zhou YC; Wang XC; Jin CG; Ye JG; Ma DD; Xie Q; Huang YG
    Anticancer Drugs; 2016 Jun; 27(5):417-26. PubMed ID: 26872308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of 90-kD heat shock protein potentiates the cytotoxicity of chemotherapeutic agents in human glioma cells.
    Ohba S; Hirose Y; Yoshida K; Yazaki T; Kawase T
    J Neurosurg; 2010 Jan; 112(1):33-42. PubMed ID: 19408974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NAD(P)H:Quinone Oxidoreductase-1 Expression Sensitizes Malignant Melanoma Cells to the HSP90 Inhibitor 17-AAG.
    Kasai S; Arakawa N; Okubo A; Shigeeda W; Yasuhira S; Masuda T; Akasaka T; Shibazaki M; Maesawa C
    PLoS One; 2016; 11(4):e0153181. PubMed ID: 27045471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aryl hydrocarbon receptor is a target of 17-Allylamino-17-demethoxygeldanamycin and enhances its anticancer activity in lung adenocarcinoma cells.
    Chen PH; Chang JT; Li LA; Tsai HT; Shen MY; Lin P
    Mol Pharmacol; 2013 Mar; 83(3):605-12. PubMed ID: 23229511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. P-Glycoprotein-mediated resistance to Hsp90-directed therapy is eclipsed by the heat shock response.
    McCollum AK; TenEyck CJ; Stensgard B; Morlan BW; Ballman KV; Jenkins RB; Toft DO; Erlichman C
    Cancer Res; 2008 Sep; 68(18):7419-27. PubMed ID: 18794130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role for NAD(P)H:quinone oxidoreductase 1 and manganese-dependent superoxide dismutase in 17-(allylamino)-17-demethoxygeldanamycin-induced heat shock protein 90 inhibition in pancreatic cancer cells.
    Siegel D; Shieh B; Yan C; Kepa JK; Ross D
    J Pharmacol Exp Ther; 2011 Mar; 336(3):874-80. PubMed ID: 21156818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Study of 17-AAG and NVP-AUY922 in Pancreatic and Colorectal Cancer Cells: Are There Common Determinants of Sensitivity?
    Mayor-López L; Tristante E; Carballo-Santana M; Carrasco-García E; Grasso S; García-Morales P; Saceda M; Luján J; García-Solano J; Carballo F; de Torre C; Martínez-Lacaci I
    Transl Oncol; 2014 Oct; 7(5):590-604. PubMed ID: 25389454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells.
    Sauvageot CM; Weatherbee JL; Kesari S; Winters SE; Barnes J; Dellagatta J; Ramakrishna NR; Stiles CD; Kung AL; Kieran MW; Wen PY
    Neuro Oncol; 2009 Apr; 11(2):109-21. PubMed ID: 18682579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones.
    Siegel D; Yan C; Ross D
    Biochem Pharmacol; 2012 Apr; 83(8):1033-40. PubMed ID: 22209713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BIIB021, a synthetic Hsp90 inhibitor, has broad application against tumors with acquired multidrug resistance.
    Zhang H; Neely L; Lundgren K; Yang YC; Lough R; Timple N; Burrows F
    Int J Cancer; 2010 Mar; 126(5):1226-34. PubMed ID: 19676042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The antiproliferative activity of the heat shock protein 90 inhibitor IPI-504 is not dependent on NAD(P)H:quinone oxidoreductase 1 activity in vivo.
    Douglas M; Lim AR; Porter JR; West K; Pink MM; Ge J; Wylie AA; Tibbits TT; Biggs K; Curtis M; Palombella VJ; Adams J; Fritz CC; Normant E
    Mol Cancer Ther; 2009 Dec; 8(12):3369-78. PubMed ID: 19952119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors.
    Centenera MM; Gillis JL; Hanson AR; Jindal S; Taylor RA; Risbridger GP; Sutherland PD; Scher HI; Raj GV; Knudsen KE; Yeadon T; ; Tilley WD; Butler LM
    Clin Cancer Res; 2012 Jul; 18(13):3562-70. PubMed ID: 22573351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Hsp90: small-molecule inhibitors and their clinical development.
    Taldone T; Gozman A; Maharaj R; Chiosis G
    Curr Opin Pharmacol; 2008 Aug; 8(4):370-4. PubMed ID: 18644253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple kinase pathways involved in the different de novo sensitivity of pancreatic cancer cell lines to 17-AAG.
    Liu H; Zhang T; Chen R; McConkey DJ; Ward JF; Curley SA
    J Surg Res; 2012 Jul; 176(1):147-53. PubMed ID: 22099584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sulforaphane potentiates the efficacy of 17-allylamino 17-demethoxygeldanamycin against pancreatic cancer through enhanced abrogation of Hsp90 chaperone function.
    Li Y; Zhang T; Schwartz SJ; Sun D
    Nutr Cancer; 2011; 63(7):1151-9. PubMed ID: 21875325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The bioreduction of a series of benzoquinone ansamycins by NAD(P)H:quinone oxidoreductase 1 to more potent heat shock protein 90 inhibitors, the hydroquinone ansamycins.
    Guo W; Reigan P; Siegel D; Zirrolli J; Gustafson D; Ross D
    Mol Pharmacol; 2006 Oct; 70(4):1194-203. PubMed ID: 16825487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.